Abstract
In ulcerative colitis, mucosal healing has clearly been incorporated in the assessment of treatment efficacy. In Crohn’s disease, this concept has only emerged in recent clinical trials with biological therapies. Systemic steroids don’t reliably induce mucosal healing in Crohn’s disease, but purine analogues and anti-TNF agents have a potential to heal mucosal ulcerations. Evidence for mucosal healing has now been provided for the anti-TNF agents infliximab, adalimumab and certolizumab pegol. For infliximab in Crohn’s disease, mucosal healing has been associated with a reduction in clinical relapses, disease-related hospitalizations and surgeries. On the contrary, the benefit of treating asymptomatic patients with IBD more intensively until they achieve mucosal healing has not been proven. In clinical practice, assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy as well as in patients where treatment discontinuation is being considered.
Keywords: Crohn’s disease, endoscopy, endpoint, ibd, inflammatory bowel disease, medical therapy, mucosal healing, outcome, ulcerative colitis, anti-TNF agents, endpoint, purine analogues.
Current Drug Targets
Title:Medical Therapy and Mucosal Healing
Volume: 13 Issue: 10
Author(s): Marc Ferrante and Gert Van Assche
Affiliation:
Keywords: Crohn’s disease, endoscopy, endpoint, ibd, inflammatory bowel disease, medical therapy, mucosal healing, outcome, ulcerative colitis, anti-TNF agents, endpoint, purine analogues.
Abstract: In ulcerative colitis, mucosal healing has clearly been incorporated in the assessment of treatment efficacy. In Crohn’s disease, this concept has only emerged in recent clinical trials with biological therapies. Systemic steroids don’t reliably induce mucosal healing in Crohn’s disease, but purine analogues and anti-TNF agents have a potential to heal mucosal ulcerations. Evidence for mucosal healing has now been provided for the anti-TNF agents infliximab, adalimumab and certolizumab pegol. For infliximab in Crohn’s disease, mucosal healing has been associated with a reduction in clinical relapses, disease-related hospitalizations and surgeries. On the contrary, the benefit of treating asymptomatic patients with IBD more intensively until they achieve mucosal healing has not been proven. In clinical practice, assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy as well as in patients where treatment discontinuation is being considered.
Export Options
About this article
Cite this article as:
Ferrante Marc and Van Assche Gert, Medical Therapy and Mucosal Healing, Current Drug Targets 2012; 13 (10) . https://dx.doi.org/10.2174/138945012802429679
DOI https://dx.doi.org/10.2174/138945012802429679 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nano-Chitosan Particles in Anticancer Drug Delivery: An Up-to-Date Review
Mini-Reviews in Medicinal Chemistry Patent Selections
Recent Patents on Drug Delivery & Formulation Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery In the Crosshairs: NF-κB Targets the JNK Signaling Cascade
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Contrast Agents in X-Ray Computed Tomography and Its Applications in Oncology
Anti-Cancer Agents in Medicinal Chemistry Effects of Quinone Derivatives, such as 1,4-Naphthoquinone, on DNA Polymerase Inhibition and Anti-Inflammatory Action
Medicinal Chemistry Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Novel MicroRNA Signature to Differentiate Ulcerative Colitis from Crohn Disease: A Genome-Wide Study Using Next Generation Sequencing
MicroRNA Leuckart Synthesis and Pharmacological Assessment of Novel Acetamide Derivatives
Anti-Cancer Agents in Medicinal Chemistry Nutraceutical: A Drug, Dietary Supplement and Food Ingredient
Current Pharmacogenomics and Personalized Medicine Curcumin: A Dietary Phytochemical for Targeting the Phenotype and Function of Dendritic Cells
Current Medicinal Chemistry Biochemical Aspects of Nitric Oxide
Current Pharmaceutical Design Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective
Current Rheumatology Reviews Application of Decoy Oligonucleotides as Novel Therapeutic Strategy: A Contemporary Overview
Current Drug Discovery Technologies The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry Taurine and the Relevance of Supplementation in Humans, in Health and Disease
Current Nutrition & Food Science Sex Impact on Biomarkers, Pharmacokinetics and Pharmacodynamics
Current Medicinal Chemistry Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Current Drug Targets The Role of STATs in Inflammation and Inflammatory Diseases
Current Pharmaceutical Design Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Current Gene Therapy